Journal of Bone and Mineral Metabolism

, Volume 28, Issue 5, pp 554–560

Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus

  • Ippei Kanazawa
  • Toru Yamaguchi
  • Masahiro Yamamoto
  • Toshitsugu Sugimoto
Original Article

Abstract

Although previous studies indicated that hypoglycemic agents could affect bone metabolism, little is known about whether these agents are associated with the risks of osteoporotic fracture in Japanese patents with type 2 diabetes. We examined whether treatments of diabetes, such as insulin administration, sulfonylurea, thiazolidinedione, and metformin, were associated with the presence of vertebral fractures in 494 men and 344 postmenopausal women with type 2 diabetes. We analyzed the relationships between each treatment versus bone turnover markers, bone mineral density (BMD), and the presence of prevalent vertebral fractures. Multiple logistic regression analysis adjusted for age, duration of diabetes, body mass index, serum creatinine, serum C-peptide, and HbA1c showed that, in postmenopausal women, treatments with insulin administration or thiazolidinedione were significantly and positively associated with the presence of vertebral fractures [odds ratio (OR) = 2.27, P = 0.012 and OR = 3.38, P = 0.038, respectively], whereas treatment with sulfonylurea was significantly and inversely associated with vertebral fractures (OR = 0.48, P = 0.018). These relationships were still significant after additional adjustment for lumbar BMD. In contrast, no significant relationships between treatments with any agent and the presence of vertebral fractures were found in men. These findings suggest that postmenopausal women treated with insulin or thiazolidinedione have a high risk of vertebral fractures independent of age, body stature, blood glucose level, insulin secretion, or BMD whereas treatment with sulfonylurea is associated with a decreased risk.

Keywords

Thiazolidinedione Insulin Sulfonylurea Type 2 diabetes mellitus Vertebral fracture 

References

  1. 1.
    Barrett-Connor E, Holbrook TL (1992) Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA 268:3333–3337CrossRefPubMedGoogle Scholar
  2. 2.
    Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878–882CrossRefPubMedGoogle Scholar
  3. 3.
    Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556–561CrossRefPubMedGoogle Scholar
  4. 4.
    Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes: a meta-analysis. Osteoporos Int 18:427–444CrossRefPubMedGoogle Scholar
  5. 5.
    Lipscombe LL, Jamal SA, Booth GL, Hawker GA (2007) The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care 30:835–841CrossRefPubMedGoogle Scholar
  6. 6.
    Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, Tylavsky FA, de Rekeneire N, Harris TB, Newman AB (2005) Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the Health, Aging, and Body Composition Study. Arch Intern Med 165:1612–1617CrossRefPubMedGoogle Scholar
  7. 7.
    Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T (2009) Diabetic patients have an increased risk of vertebral fractures independent of bone mineral density or diabetic complications. J Bone Miner Res 24:702–709CrossRefPubMedGoogle Scholar
  8. 8.
    Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RI (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226–1235CrossRefPubMedGoogle Scholar
  9. 9.
    Tornvig L, Mosekilde LI, Justesen J, Falk E, Kassem M (2001) Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 69:46–50CrossRefPubMedGoogle Scholar
  10. 10.
    Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H (2004) PPAR-γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846–855PubMedGoogle Scholar
  11. 11.
    Pei L, Tontonoz P (2004) Fat’s loss is bone’s gain. J Clin Invest 113:805–806PubMedGoogle Scholar
  12. 12.
    Soroceau MA, Miao D, Bai X-Y, Su H, Goltzman D, Karaplis AC (2004) Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183:203–216CrossRefGoogle Scholar
  13. 13.
    Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401–406CrossRefPubMedGoogle Scholar
  14. 14.
    Loke YK, Singh S, Furberg CD (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ (Can Med Assoc J) 180:32–39CrossRefGoogle Scholar
  15. 15.
    Thomas DM, Hards DK, Rogers SD, Ng KW, Best JD (1997) Insulin and bone, clinical and scientific view. Endocrinol Metab N Am 4:5–17Google Scholar
  16. 16.
    Thomas DM, Hards DK, Rogers SD, Ng KW, Best JD (1996) Insulin receptor expression in bone. J Bone Miner Res 11:1312–1320CrossRefPubMedGoogle Scholar
  17. 17.
    Raskin P, Stevenson MRM, Barilla DE, Pak CYC (1978) The hypercalciuria of diabetes mellitus: its amelioration with insulin. Clin Endocrinol 9:329–335CrossRefGoogle Scholar
  18. 18.
    Gertner JM, Tamborlane WV, Horst RL, Sherwin RS, Felig P, Genel M (1980) Mineral metabolism in diabetes mellitus: changes accompanying treatment with portable subcutaneous insulin infusion system. J Clin Endocrinol Metab 50:862–866CrossRefPubMedGoogle Scholar
  19. 19.
    Ivers RQ, Mitchell P, Cumming RG, Peduto AJ (2001) Diabetes and risk of fractures: the Blue Mountains Eye Study. Diabetes Care 24:1198–1203CrossRefPubMedGoogle Scholar
  20. 20.
    Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S (2008) Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 23:1334–1342CrossRefPubMedGoogle Scholar
  21. 21.
    Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292–1299CrossRefPubMedGoogle Scholar
  22. 22.
    Fujimoto WY (1996) Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups. Diabetes Med 13:S7–S10CrossRefGoogle Scholar
  23. 23.
    Torrens JI, Skurnick J, Davidow AL, Korenman SG, Santoro N, Soto-Greene M, Lasser N, Weiss G, Study of Women’s Health Across the Nation (SWAN) (2004) Ethnic differences in insulin sensitivity and beta-cell function in premenapausal or early perimenopausal women without diabetes: the Study of Women’s Health Across the Nation (SWAN). Diabetes Care 27:354–361CrossRefPubMedGoogle Scholar
  24. 24.
    Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984–996CrossRefPubMedGoogle Scholar
  25. 25.
    Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2008) Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men. Calcif Tissue Int 83:324–331CrossRefPubMedGoogle Scholar
  26. 26.
    Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2007) Serum insulin-like growth factor-I is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int 18:1675–1681CrossRefPubMedGoogle Scholar
  27. 27.
    Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR (2007) The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305–1310CrossRefPubMedGoogle Scholar
  28. 28.
    Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3355CrossRefPubMedGoogle Scholar
  29. 29.
    Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G, Diabetes Outcome Progression Trial (ADOPT) Study Group (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845–851CrossRefPubMedGoogle Scholar
  30. 30.
    Schwartz AV (2008) TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008:1–6Google Scholar
  31. 31.
    Ma P, Gu B, Ma J, E L, Wu X, Gao J, Liu H (2009) Glimepiride induces proliferation and differentiation of rat osteoblasts via the PI3-kinase/Akt pathway. Metabolism. doi:10.1016/j.metabol.2009.08.003
  32. 32.
    Daughaday WH, Phillips LS, Mueller MC (1976) The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver. Endocrinology 98:1214–1219CrossRefPubMedGoogle Scholar
  33. 33.
    Scott CD, Baxter RC (1986) Production of insulin-like growth factor I and its binding protein in rat hepatocytes cultured from diabetic and insulin-treated diabetic rats. Endocrinology 119:2346–2352CrossRefPubMedGoogle Scholar
  34. 34.
    Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L (2006) Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Phamacol 536:38–46CrossRefGoogle Scholar
  35. 35.
    Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3–E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375:414–419CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2010

Authors and Affiliations

  • Ippei Kanazawa
    • 1
  • Toru Yamaguchi
    • 1
  • Masahiro Yamamoto
    • 1
  • Toshitsugu Sugimoto
    • 1
  1. 1.Department of Internal Medicine 1Shimane University Faculty of MedicineIzumoJapan

Personalised recommendations